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Background: Available data from randomized trials on thrombectomy in patients with 
ST-elevation myocardial infarction (STEMI) have shown favorable trends in myocardial reper-
fusion. However, few data are available on the effect of thrombectomy on clinical outcome. 
Thus we have designed a collaborative individual patient-data meta-analysis which aimed to 
assess the long-term clinical outcome in STEMI patients randomized to percutaneous coronary 
intervention (PCI) with or without thrombectomy.
Method: After a thorough database search, the principal investigators of randomized trials 
comparing thrombectomy with standard PCI in patients with STEMI were contacted. Principal 
investigators as authors of 11 randomized studies agreed to participate and were asked to com-
plete a structured database by providing a series of key pre-PCI clinical and angiographic data as 
well as the longest available clinical outcome of the patients enrolled in the corresponding trial. 
The primary end-point of this pooled analysis is the comparison of overall survival rates between 
patients randomized to PCI with thrombectomy or PCI without thrombectomy. The secondary 
end-points are survival free from myocardial infarction (MI), target lesion revascularization 
(TLR), major adverse coronary events (MACE: death + MI + TLR) and death + MI between 
patients randomized to PCI with thrombectomy or PCI without thrombectomy. A pre-deﬁ  ned 
subgroup analysis is planned considering the following variables: type of thrombectomy device 
used, diabetes, rescue PCI, IIb/IIIa-inhibitors use, time-to-reperfusion, infarct-related artery, 
and pre-PCI TIMI ﬂ  ow.
Implications: This study will provide useful data on the effect of the reported improved myo-
cardial perfusion associated with thrombectomy on the long-term clinical outcome in patients 
with STEMI.
Keywords: ST elevation myocardial infarction, thrombectomy, primary PCI
Introduction
Primary percutaneous coronary intervention (PCI) has been shown to provide mortality 
beneﬁ  ts in comparison with thrombolysis, mainly because of better and sustained optimal 
coronary perfusion.1 However, despite epicardial recanalization with Thrombolysis in 
Myocardial Infarction Trial 3 (TIMI 3) ﬂ  ow, myocardial reperfusion is not achieved in 
up to 40% of patients, with a signiﬁ  cant effect on their long-term survival.2,3 Athero-
thrombotic embolization is considered to play an important role in the pathogenesis of 
this “no-reﬂ  ow phenomenon.”4 Accordingly, a series of adjunctive devices with different Vascular Health and Risk Management 2009:5 244
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antiembolic properties (thrombectomy or distal protection) 
has been developed and tested in clinical studies with con-
ﬂ  icting results. Nevertheless, a meta-analysis of prospective 
randomized trials5 suggests that the use of thrombectomy 
devices, but not distal protection devices, may be associated 
with a signiﬁ  cant reduction of angiographically evident distal 
embolization and with higher rates of myocardial blush grade 
(MBG) 3 and ST-segment resolution.
Because angiographic and electrocardiographic markers 
of myocardial reperfusion are well known predictors of late 
clinical outcome,3,6–9 the use of thrombectomy may also trans-
late to a clinical advantage. Unfortunately, most of the trials 
on thrombectomy have been based on a small sample size 
and short follow-up for reliable assessment of clinical beneﬁ  t. 
Only one, recently published, single-center trial conducted 
on 1071 patients with ST-elevation myocardial infarction 
(STEMI), showed an advantage of thrombus-aspiration use 
in terms of mortality at one year follow-up.10
To extend the investigation on this issue to a larger popu-
lation, we have designed a pooled analysis of the individual 
patient data of prospective randomized trials comparing 
standard PCI with or without thrombectomy, to evaluate the 
inﬂ  uence of thrombectomy use on clinical outcome.
Design and method
Study design
Individual patient data meta-analysis. The study protocol 
was initiated in October 2007 (by FB, MDV, and FC) and 
the ﬁ  rst ﬁ  nal manuscript design drafting was completed on 
January 10th, 2008.
Method
A systematic MEDLINE database search (see http://www.
ncbi.nlm.nih.gov/) for studies comparing standard PCI 
with thrombectomy (T) with standard PCI only (SP) was 
conducted according to a modiﬁ  ed Robinson and Dickersin 
strategy.11 Keywords were “STEMI,” “randomized,” 
“thrombus aspiration,” and “thrombectomy.” The TCTMD 
(see http://www.tctmd.com/), EuroPCR (see http://www.
europcr.com/), American College of Cardiology (see 
http://www.acc.org/), America Heart (see http://www.
americaheart.org/), and European Society of Cardiology 
(see http://www.escardio.org/) websites were searched for 
pertinent abstracts and expert slide presentations between 
October 2003 and February 2008. No language restriction 
was applied.
Inclusion criteria for selected studies were: 1. comparison 
of T with SP in patients with STEMI; 2. randomized 
treatment allocation. The exclusion criterion was the 
equivocal treatment allocation process.
Thirteen studies published as full papers12–24 and four 
additional studies25–28 published as abstracts and/or slide 
presentations (Noel B,28 from the EuroPCR 2005 meeting; 
the PIHRATE trial;25 the expert slide presentation from 
the TCTMD 2007 meeting; the EXPIRA trial;26 expert 
slide presentations on the Transcatheter Cardiovascular 
Therapeutics website (see http://www.tct2007.com/); 
and the Export study27 expert slide presentations on the 
Transcatheter Cardiovascular Therapeutics website were 
identiﬁ  ed.
The 15 principal investigators of these 17 identiﬁ  ed studies 
were contacted by mail or fax to participate in the ATTEMPT 
study (meta-Analysis of Trials on ThrombEctomy in acute 
Myocardial infarction based on individual PatienT data), a 
meta-analysis based on individual patient data to compare 
the long-term clinical outcome between thrombectomy and 
standard PCI in patients with STEMI enrolled in the selected 
randomized trials.
All 10 principal investigators who agreed to participate 
were asked to complete a structured database including 
standard baseline clinical and angiographic data as well as 
the longest available clinical outcome data of each patient 
previously enrolled in the corresponding trial.
This individual patient data will be sent to the study 
coordinator (MDV) who will be responsible for the ﬁ  nal 
pooling in a single database.
A statistical expert (GBZ) will be responsible for statisti-
cal analyses. All the principal investigators will be informed 
about the status of the project by regular newsletters.
End points
The primary end-point of the study will be to compare rates of 
overall survival in patients randomized to T or SP. Secondary 
end-points will be survival free from myocardial infarction 
(MI), target lesion revascularization (TLR), major adverse 
coronary events (MACE: death + MI + TLR) and death + 
MI between patients randomized to T or SP.
Pre-deﬁ  ned subgroup analyses
The comparison of clinical outcome between patients ran-
domized to T and SP will be performed according to:
1.  Type of thrombectomy device (manual thrombus 
aspiration devices versus non-manual thrombectomy 
devices)
2.  Presence or absence of diabetes mellitus
3.  Rescue PCI or primary PCIVascular Health and Risk Management 2009:5 245
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4.  Administration or no administration of IIb/IIIa-inhibitors
5. Time-to-reperfusion  (3 h or between 3 h and 6 h 
or 6 h)
6.  Infarct-related artery (LAD or LCX or RCA)
7. Pre-PCI  TIMI  ﬂ  ow (TIMI 0–1 or TIMI 2–3)
Sample size calculation and study 
feasibility
A meta-analysis of randomized trials comparing 
thrombectomy with standard PCI in patients with STEMI5 
showed a rate of myocardial blush grade 3 (MBG 3) 
signiﬁ  cantly higher in the thrombectomy group: odds ratio 
[OR] 2.32 (1.28–4.21). Moreover, van’t Hof and colleagues 
demonstrated that the post-PCI MBG is a strong predic-
tor of long-term mortality in patients with STEMI treated 
with primary PCI. In particular they reported, after a mean 
follow-up of 1.9 ± 1.7 years, a total mortality rate of 3% in 
patients with post-PCI MBG 3 and of 29% in patients with 
post-PCI MBG  3.3 Given these results, we anticipated a 
sample size of 1350 patients to demonstrate an advantage 
in terms of mortality at one year using thrombectomy, with 
an alpha risk of 5% and a beta risk of 20%.
Study population
To date, 10 principal investigators of 11 randomized studies 
agreed to participate in the ATTEMPT study and provided the 
requested data. The key characteristics of these 11 randomized 
studies are summarized in Table 1.
The ATTEMPT study population will comprise all the 
patients enrolled in the randomized studies entered in this 
single patient data meta-analysis. The key characteristics 
of the study populations recruited in the 11 studies are 
summarized in Table 2.
Statistical analysis
Continuous variables will be reported as mean ± standard 
deviation or median (1st–3rd quartiles), and categorical 
variables as n (%), unless otherwise stated. Statistical 
pooling will be based on the Peto ﬁ  xed effect method for 
patient-level analysis (according to event counts reported 
at the longest available follow-up), and a random effect 
method with generic inverse variance weighting (according 
to risk estimates obtained with Cox proportional hazard 
analysis). In this way we can compute pooled OR and 
hazard ratios (HR) with their corresponding 95% conﬁ  -
dence intervals. Kaplan–Meier curves will be computed for 
survival and event-free survival analyses, both crude and 
stratiﬁ  ed by study, with statistical testing based on log-rank 
test. Multivariable analyses, logistic or proportional hazard 
as appropriate will also be conducted by clustering patients 
according to each study. A two-tailed p value of 0.05 was 
chosen as the cut-off for statistical signiﬁ  cance at hypothesis 
testing, whereas we plan to appraise statistical inconsistency 
by means of I2, with values  50% identifying subsets with 
at least moderate heterogeneity. Finally, publication bias 
will be appraised by means of funnel plot inspection and 
Egger test.
Table 1 Key characteristics of the trials entered in the ATTEMPT study
Study Design Thrombectomy 
device
Number of patients 
SP T
Pre-coronary time 
limit (hours)
Longest published 
clinical FU
VAMPIRE19 Multicenter TVAC 175 180 24 In hospital
X-AMINE ST17 Multicenter X-Sizer 101 100 12 Six months
DEAR-MI (19) Single center Pronto 74 74 12 In hospital
Antoniucci et al14 Single center Angiojet 50 50 6 30 days
REMEDIA16 Single center Diver CE 50 49 12 In hospital
Noel et al28 Single center Export 26 24 12 In hospital
Kaltoft et al20 Single center Rescue 107 108 12 30 days
De Luca et al21 Single center Diver CE 38 38 12 Six months
PIHRATE25 Multicenter Diver CE 94 102 6 Six months
EXPIRA26 Single center Export 87 88 12 Nine months
TAPAS trial24 Single center Export 536 535 12 One year
ATTEMPT study 
population
–– 1338 1348 ––
Abbreviations: FU, follow-up; NA, not available; PCI percutaneous coronary intervention; SP, standard PCI;   T, thrombectomy device treatment.Vascular Health and Risk Management 2009:5 246
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Discussion
The clinical data from a meta-analysis of 18 trials on adjunctive 
devices in patients with STEMI show that use of thrombec-
tomy devices is associated with better myocardial reperfusion, 
which does not translate, however, to a lower rate of mortality 
or MI at 30 days.5 This short follow-up time might be insuf-
ﬁ  cient to show a clinical beneﬁ  t. Of note, two recent non-
randomized studies comparing Angio-jet with SP in STEMI 
patients with a high thrombus burden reported a signiﬁ  cant 
reduction of long-term mortality.29,30 Moreover, very recent 
data from the randomized EXPIRA trial (Sardella, personal 
communication at TCT 2007 meeting) and the randomized 
TAPAS trial showed respectively a strong trend toward lower 
mortality at nine months26 and a signiﬁ  cantly lower mortality 
at 12 months in the group of patients treated with throm-
bectomy.10 Therefore the available data support the possible 
advantage of thrombectomy on long-term clinical outcome. 
Because angiographic analyses have shown that thrombectomy 
may have different efﬁ  cacy in different patients,31 the clinical 
beneﬁ  t of thrombectomy use may be more pronounced in some 
subgroups of patients. Thus previous studies showed a greater 
advantage using thrombectomy for reperfusion in patients 
with baseline TIMI ﬂ  ow 0–1, baseline thrombus score 3–4 
or angiographically evident thrombus-containing lesions.16,22 
For these reasons, the design of the present study planned for 
subgroup analyses of patients stratiﬁ  ed according to a series of 
key clinical, angiographic, and procedural variables.
In conclusion the aim of the ATTEMPT study is to assess 
if thrombectomy, by improving myocardial reperfusion, 
can inﬂ  uence the long-term clinical outcome in particular 
in some high risk subgroups of STEMI patients such as 
those with a higher thrombus burden or a large amount of 
myocardium at risk.
Expected study limitations
As a consequence of the ATTEMPT study design, the quality 
of the results will be inﬂ  uenced by the quality of the design of 
each original trial. In particular, no quality control has been 
planned so that each participant principal investigator will 
be completely responsible for the quality control of the data 
entered in the ATTEMPT database. No restriction in trial 
size, publication status (full paper or abstract presentation) 
and length of updated clinical follow-up has been applied. 
Consequently, some of the trials included are single-center 
and/or small-sized, and the length of patient follow-up will 
be not uniform.
All these anticipated limitations have been accepted in an 
effort to achieve the goal of wide participation in the study. 
Such extensive collaboration was sought to better summarize 
the available data obtained to date by the scientiﬁ  c com-
munity. Thus publication bias assessment has been planned 
according to validated statistical techniques.
Another possible limitation may arise from the fact that 
different deﬁ  nitions may have been adopted across the trials 
included in the analysis. In particular, the deﬁ  nition of device 
failure differed across the studies so that a reliable pooled esti-
mate of device efﬁ  cacy will not be possible. Nevertheless, the 
planned primary “intention-to-treat” analysis selected for the 
Table 2 Key characteristics of the study population in the 11 trials entered in the ATTEMPT study
Study Age 
(mean)
Diabetes 
(%)
IIb/IIIa 
inhibitors 
(%)
Failed 
TL (%)
Anterior 
MI ¶(%)
Mean 
symptom-to 
balloon time 
(minutes)
Baseline TIMI 
ﬂ  ow 0–1 (%)
VAMPIRE19 63 26 0 0 51 291* 75
X-AMINE ST17 61 22 51 0 52 257 100
DEAR-MI18 59 18 100 0 47 130 78
Antoniucci et al14 65 17 98 0 40 249 78
REMEDIA16 60 21 69 38 45 280§ 88
Noel et al28 60 13 NA 34 44 282 NA
Kaltoft et al20 64 7 95 0 44 225 69
De Luca et al21 65 21 100 0 100 438 100
PIHRATE25 60 10 62 0 NA 200 100
EXPIRA26 66 17 75 0 100 390 100
TAPAS study24 63 12 92 0 43 187 57
Abbreviations: MI, myocardial infarction; TS, thrombolysis; ¶, in the studies with missing anterior MI rate patients with left anterior descending artery as culprit artery where 
considered to have anterior MI; §, symptom to angiography time; *, symptom to hospital admission time; NA, not available.Vascular Health and Risk Management 2009:5 247
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present study is not expected to be inﬂ  uenced by such factors. 
Moreover, the presence of (minor) heterogeneity among some 
clinical end-point (like myocardial infarction, target vessel, or 
target lesion revascularization) deﬁ  nitions adopted across the 
trials will not inﬂ  uence the primary end-point analysis which 
is focused on the univocal all-cause mortality.
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